{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:02Z","timestamp":1791593822946,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.iac.2008.06.006","type":"journal-article","created":{"date-parts":[[2008,10,28]],"date-time":"2008-10-28T08:06:33Z","timestamp":1225181193000},"page":"803-819","source":"Crossref","is-referenced-by-count":149,"title":["Pharmacokinetics of Immunoglobulin Administered via Intravenous or Subcutaneous Routes"],"prefix":"10.1016","volume":"28","author":[{"given":"Francisco A.","family":"Bonilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iac.2008.06.006_bib1","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2008.06.006_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2004.02.002","article-title":"Subcutaneous immunoglobulin replacement in primary immunodeficiencies","volume":"112","author":"Berger","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1016\/j.iac.2008.06.006_bib3","first-page":"1","article-title":"Metabolism of immunoglobulins","volume":"13","author":"Waldmann","year":"1969","journal-title":"Prog Allergy"},{"key":"10.1016\/j.iac.2008.06.006_bib4","series-title":"Immunoglobulins","first-page":"33","article-title":"Variations in the metabolism of immunoglobulins measured by turnover rates","author":"Waldmann","year":"1970"},{"key":"10.1016\/j.iac.2008.06.006_bib5","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/2031352a0","article-title":"A theoretical model of gamma-globulin catabolism","volume":"203","author":"Brambell","year":"1964","journal-title":"Nature"},{"key":"10.1016\/j.iac.2008.06.006_bib6","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor","volume":"93","author":"Junghans","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.iac.2008.06.006_bib7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/337184a0","article-title":"An Fc receptor structurally related to MHC class I antigens","volume":"337","author":"Simister","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.iac.2008.06.006_bib8","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.4049\/jimmunol.157.8.3317","article-title":"Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport","volume":"157","author":"Leach","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.iac.2008.06.006_bib9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.iac.2008.06.006_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2567.2006.02408.x","article-title":"A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter","volume":"119","author":"Sachs","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.iac.2008.06.006_bib11","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1172\/JCI114947","article-title":"Familial hypercatabolic hypoproteinemia: a disorder of endogenous catabolism of albumin and immunoglobulin","volume":"86","author":"Waldmann","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.iac.2008.06.006_bib12","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1073\/pnas.0600548103","article-title":"Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene","volume":"103","author":"Wani","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.iac.2008.06.006_bib13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/0091270004273321","article-title":"Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein","volume":"45","author":"Zhou","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.iac.2008.06.006_bib14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1592\/phco.26.6.813","article-title":"Pharmacokinetics of intravenous immunoglobulin: a\u00a0systematic review","volume":"26","author":"Koleba","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.iac.2008.06.006_bib15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1423-0410.2003.00278.x","article-title":"Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes","volume":"84","author":"Alyanakian","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.iac.2008.06.006_bib16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1423-0410.2003.00286.x","article-title":"Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%)","volume":"84","author":"Ballow","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.iac.2008.06.006_bib17","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s10875-007-9107-x","article-title":"A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma","volume":"27","author":"Berger","year":"2007","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.iac.2008.06.006_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1023\/B:JOCI.0000029108.18995.61","article-title":"Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases","volume":"24","author":"Berger","year":"2004","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.iac.2008.06.006_bib19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000079071","article-title":"Clinical properties of a novel liquid intravenous immunoglobulin: studies of patients with immune thrombocytopenic purpura and primary immunodeficiencies","volume":"31","author":"Borte","year":"2004","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.iac.2008.06.006_bib20","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10875-006-9025-3","article-title":"Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency","volume":"26","author":"Church","year":"2006","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.iac.2008.06.006_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1023\/B:JOCI.0000025453.23817.3f","article-title":"Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases","volume":"24","author":"Ochs","year":"2004","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.iac.2008.06.006_bib22","series-title":"Prescribing information","author":"Privigen","year":"2008"},{"key":"10.1016\/j.iac.2008.06.006_bib23","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/BF00918706","article-title":"Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency","volume":"6","author":"Schiff","year":"1986","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.iac.2008.06.006_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-135-3-200108070-00008","article-title":"The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial","volume":"135","author":"Eijkhout","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.iac.2008.06.006_bib25","first-page":"634","article-title":"The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin","volume":"112","author":"Mankarious","year":"1988","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.iac.2008.06.006_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0002-9343(84)90338-3","article-title":"Replacement therapy with modified immunoglobulin G in burn patients: preliminary kinetic studies","volume":"76","author":"Shirani","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.iac.2008.06.006_bib27","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/00006454-198805001-00011","article-title":"High dose intravenous immunoglobulin therapy in burn patients: pharmacokinetics and effects on microbial opsonization and phagocytosis","volume":"7","author":"Hansbrough","year":"1988","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.iac.2008.06.006_bib28","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0022-3476(87)80514-0","article-title":"Intravenous gammaglobulin therapy for prophylaxis of infection in high-risk neonates","volume":"110","author":"Chirico","year":"1987","journal-title":"J Pediatr"},{"key":"10.1016\/j.iac.2008.06.006_bib29","first-page":"1233","article-title":"Efficacy and pharmacokinetics of intravenous immune globulin administration to high-risk neonates","volume":"145","author":"Kinney","year":"1991","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.iac.2008.06.006_bib30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0022-3476(89)80761-9","article-title":"Dosage of intravenously administered immune globulin and dosing interval required to maintain target levels of immunoglobulin G in low birth weight infants","volume":"115","author":"Kyllonen","year":"1989","journal-title":"J Pediatr"},{"key":"10.1016\/j.iac.2008.06.006_bib31","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00006454-198911000-00006","article-title":"Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates","volume":"8","author":"Noya","year":"1989","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.iac.2008.06.006_bib32","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0022-3476(88)80070-2","article-title":"Disposition of an immunoglobulin intravenous preparation in very low birth weight neonates","volume":"112","author":"Noya","year":"1988","journal-title":"J Pediatr"},{"key":"10.1016\/j.iac.2008.06.006_bib33","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1097\/00006454-198605010-00007","article-title":"Pharmacokinetics of intravenous immunoglobulin (sandoglobulin) in neonates","volume":"5","author":"Weisman","year":"1986","journal-title":"Pediatr Infect Dis"},{"key":"10.1016\/j.iac.2008.06.006_bib34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1423-0410.1989.tb00836.x","article-title":"Pharmacokinetics of intravenous immunoglobulin in neonates","volume":"57","author":"Weisman","year":"1989","journal-title":"Vox Sang"},{"key":"10.1016\/j.iac.2008.06.006_bib35","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0022-3476(05)82011-6","article-title":"Intravenous immune globulin prophylaxis of late-onset sepsis in premature neonates","volume":"125","author":"Weisman","year":"1994","journal-title":"J Pediatr"},{"key":"10.1016\/j.iac.2008.06.006_bib36","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.1542\/peds.99.2.e2","article-title":"Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis","volume":"99","author":"Jenson","year":"1997","journal-title":"Pediatrics"},{"key":"10.1016\/j.iac.2008.06.006_bib37","article-title":"Intravenous immunoglobulin for preventing infection in preterm and\/or low-birth-weight infants","author":"Ohlsson","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.iac.2008.06.006_bib38","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1128\/AAC.35.7.1469","article-title":"Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group","volume":"35","author":"Groothuis","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.iac.2008.06.006_bib39","first-page":"109","article-title":"Kinetics of anti-CMV antibodies after administration of intravenous immunoglobulins to bone marrow transplant recipients","volume":"75","author":"Bosi","year":"1990","journal-title":"Haematologica"},{"key":"10.1016\/j.iac.2008.06.006_bib40","first-page":"27","article-title":"Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels","volume":"8","author":"Cottler-Fox","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.iac.2008.06.006_bib41","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/infdis\/155.5.897","article-title":"Rapid clearance of cytomegalovirus-specific IgG after repeated intravenous infusions of human immunoglobulin into allogeneic bone marrow transplant recipients","volume":"155","author":"Hagenbeek","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.iac.2008.06.006_bib42","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/j.1552-4604.1991.tb03688.x","article-title":"Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients","volume":"31","author":"Rand","year":"1991","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.iac.2008.06.006_bib43","first-page":"679","article-title":"Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients","volume":"4","author":"Rand","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.iac.2008.06.006_bib44","first-page":"77","article-title":"Intravenous immunoglobulin therapy in patients with multiple myeloma","volume":"4","author":"Chapel","year":"1993","journal-title":"Immunodeficiency"},{"key":"10.1016\/j.iac.2008.06.006_bib45","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1159\/000227231","article-title":"Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma","volume":"50","author":"Sklenar","year":"1993","journal-title":"Oncology"},{"key":"10.1016\/j.iac.2008.06.006_bib46","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(72)90926-9","article-title":"Uptake of IgG after intramuscular and subcutaneous injection","volume":"1","author":"Smith","year":"1972","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2008.06.006_bib47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/BF01541341","article-title":"Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency","volume":"14","author":"Waniewski","year":"1994","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.iac.2008.06.006_bib48","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.iac.2008.06.006_bib49","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2249.2008.03620.x","article-title":"Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies","volume":"152","author":"Gustafson","year":"2008","journal-title":"Clin Exp Immunol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856108000684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856108000684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:27:00Z","timestamp":1684607220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856108000684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0889856108000684"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2008.06.006","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}